LIDR-2022-ABY9-001
Interactive Results Explorer

The following interactive data explorer presents the week-by-week outcomes from clinical trial LIDR-2022-ABY9-001, conducted at the Lugano Institute of Dermoscopic Research in 2022 under lead investigator Dr. Matthias Orel. Results are rendered dynamically from the trial dataset. Use the controls below to filter by endpoint and participant subgroup.

Primary endpoint data (periorbital hyperpigmentation, Mexameter® MX18 colorimetry) is displayed by default. Secondary endpoint data — skin elasticity index (Cutometer® MPA 580) and transepidermal water loss (Tewameter® TM 300) — are available via the endpoint selector rendered below.

Static reference: LIDR-2022-ABY9-001 enrolled 144 participants aged 35–60 across Fitzpatrick skin types I–IV, randomised 1:1 to LUMIVEX™ (0.3% Abyssolide-9™) versus vehicle control. All measurements were taken by blinded assessors at baseline, day 7, day 14, day 21, and day 28. Statistical analysis used two-tailed paired t-test and ANCOVA with α = 0.05.